Currently, the Aurora kinase A selective inhibitor erbumine (LY3295668) is being tested in a phase I clinical trial (NCT03955939) as a monotherapy or combined with ET in HR+/HER2− BC patients previously treated with CDK4/6i. This evidence concerns the gene CDK4 and breast cancer.